CTSO

CytoSorbentsC

Nasdaq / Health Care Equipment & Services

At close

2026-07-23

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$0.70

+93.7% vs current

Most likely

Base case

45%

Probability

Target price

$0.30

-17.0% vs current

B-

Bear case

30%

Probability

Target price

$0.15

-58.5% vs current

AI sentiment snapshot

Latest data as of 2026-07-01

AI commentary

Primary-source evidence improved versus the prior baseline because the company provided a fresh June 24 regulatory update and a detailed May 13 earnings release, but the overall setup still looks like a cautious monitoring case, not a clean turnaround. The deterministic prior turned negative, the stock remained at $0.374 on June 30, 2026, and I did not verify a trustworthy post-print analyst-revision set or durable positive market-reaction signal, so confidence should stay moderate rather than aggressive.

RankAlpha Sentiment Codex - 2026-07-01

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-31eventAugust 2026 FDA pre-submission meetings on ticagrelor and DOAC programsHigh impact

CytoSorbents disclosed on June 24, 2026 that it scheduled two FDA pre-submission meetings in August 2026 to discuss its ticagrelor and DOAC programs, making regulatory feedback the clearest near-term operating catalyst after the Q1 update [#8-K-2026-06-25].

2026-09-28eventNasdaq minimum-bid compliance deadline remains a hard equity overhangHigh impact

Nasdaq gave CTSO until September 28, 2026 to regain compliance with the $1.00 minimum bid requirement; with the anchor price still at $0.374 on June 30, 2026, the stock remains exposed to reverse-split or listing-risk headlines if it cannot sustain a recovery [#8-K-2026-04-02].

2026-12-31catalystLiquidity stabilization must offset going-concern pressureHigh impact

Q1 revenue rose only 2% to $8.9 million, cash fell to about $6.4 million, and management said additional capital may be needed if operating improvements and regulatory milestones do not arrive fast enough; that keeps financing execution and cash-burn control central to the thesis [#SEC-8K-2026-05-13] [#10-Q-2026-05-13].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-01 • Updated nightlySource: Internal modelMethodology